DTIL - Precision BioSciences, Inc.
| Previous Close | 12.46 |
| Open | 12.45 |
| Bid | 13.17 x 1100 |
| Ask | 13.22 x 800 |
| Day's Range | 12.21 - 13.50 |
| 52 Week Range | 11.77 - 19.00 |
| Volume | 135,555 |
| Avg. Volume | 282,491 |
| Market Cap | 663.767M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.34 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.33 |
- GlobeNewswire•6 days ago
Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer
“We are thrilled to welcome Chris Heery as our Chief Medical Officer. Chris has exceptional experience in the rapidly evolving field of cell therapies and has led many first-in-human clinical trials during his time at the National Cancer Institute (NCI).
- GlobeNewswire•11 days ago
Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
DURHAM, N.C., May 09, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary.
- Associated Press•21 days ago
Precision BioSciences: 1Q Earnings Snapshot
The Durham, North Carolina-based company said it had a loss of $1.99 per share. Losses, adjusted for non-recurring costs, were $1.19 per share. The genome editing company posted revenue of $5.5 million ...
- GlobeNewswire•21 days ago
Precision BioSciences Reports First Quarter 2019 Financial Results
DURHAM, N.C., April 29, 2019 -- Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) (“Precision”) through the application of its.
- GlobeNewswire•26 days ago
Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
DURHAM, N.C., April 24, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS®.
- GlobeNewswire•last month
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
Precision BioSciences (DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today it has dosed the first patient in the Phase 1/2a clinical trial of PBCAR0191, its first gene-edited allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate. Precision is developing PBCAR0191 in collaboration with Servier, an international pharmaceutical company.
- Barrons.com•2 months ago
A Fidelity-Affiliated VC Fund Has Made Millions from This Biotech Stock IPO
Precision Biosciences stock is now below the IPO price, but F-Prime still has millions in paper profits. F-Prime is owned by the family that controls Fidelity Investments.
- GlobeNewswire•2 months ago
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
DURHAM, N.C., April 01, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS.
- American City Business Journals•2 months ago
By the numbers: Precision Biosciences' largest shareholders
It’s been a good week for some Precision Biosciences executives and investors, whose shares of the Triangle’s newest public company are now worth millions.
- GlobeNewswire•2 months ago
Precision BioSciences Announces Pricing of Initial Public Offering
DURHAM, N.C., March 27, 2019 -- Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS.
- Benzinga•2 months ago
The Precision Biosciences IPO: What You Need To Know
Gene therapy is in vogue among biotech investors, and Precision Biosciences (DTIL), which operates in the sector, is planning an initial public offering . The Offering The company will issue 7.9 million ...
- Benzinga•2 months ago
IPO Outlook For The Week: Biopharm, Gene Editor And Lyft
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Genfit S.A. (GNFT) will issue 5 million shares at $26.33 each Wednesday ...
